Headset glasses flickering at 40 hertz miss their main goal against Alzheimer's, but the maker sees benefit in mild patients
Cognito Therapeutics still plans to seek US approval next year; independent experts speak of a signal that has yet to be proven.
US company Cognito Therapeutics on Monday presented results from a year-long study of its Spectris device at the Clinical Trials on Alzheimer's Disease conference in Boston. The device resembles sunglasses with headphones and delivers light and sound stimuli at 40 hertz, the frequency of so-called gamma waves in the brain. IEEE Spectrum reports that 673 people with mild to moderate Alzheimer's took part; about half received a sham version. Across the whole group, the difference from the sham treatment was not statistically significant.
Among the 395 participants with mild disease, decline on a standard clinical scale was about half as fast as in the control group, according to IEEE Spectrum, and those who used the device almost daily did even better. The Boston Globe reports that the results have not yet been peer reviewed and that Cognito plans to submit them to the New England Journal of Medicine. According to the paper, the company intends to seek approval from the US FDA in 2027. Side effects were limited to occasional headaches or ringing in the ears.
Independent researchers remain cautious. Paul Aisen of the University of Southern California told IEEE Spectrum the main result was simply negative and the positive subgroups exploratory. Heather Snyder of the Alzheimer's Association saw a hint of benefit that still needs confirming, according to The Boston Globe. MIT neuroscientist Li-Huei Tsai, who developed the method in mice and co-founded the company, did respond enthusiastically.